Johnson & Johnson Stock News

© Reuters. FILE PHOTO: Bottles of Johnson & Johnson’s baby powder line a drugstore shelf in New York October 15, 2015. REUTERS/Lucas Jackson/File Photo By Dietrich Knauth (Reuters) -A Johnson & Johnson (NYSE:) subsidiary came under attack in court on Monday for attempting to use the bankruptcy process to resolve tens of thousands of claims …

A Johnson & Johnson subsidiary on Monday kicked off a courtroom battle that aims to use the bankruptcy process to resolve tens of thousands of claims that the company''s baby powder and other talc-based products caused cancer.

A Johnson & Johnson subsidiary on Monday kicked off a courtroom battle that aims to use the bankruptcy process to resolve tens of thousands of claims that the company’s baby powder and other talc-based products caused cancer. More than 38,000 plaintiffs have alleged the company’s talc products caused ovarian cancer and mesothelioma, a deadly cancer […]

NEW YORK, United States, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Facts and Factors has published a new research report titled "Irritable Bowel Syndrome (IBS) Diagnostics Market By Type (IBS-C, IBS-D and Mixed IBS), By Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, & Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, & Online Pharmacies), and By Regions Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast, 2021 2026" in its research database. "According to the latest research study, the demand of global Irritable Bowel Syndrome (IBS) Diagnostics Market size & share was valued at approximately USD 1.2 Billion in 2020 and is expected to reach a value of around USD 2.3 Billion by 2026, at a compound annual growth rate (CAGR) of about 9.7% during the forecast period 2021 to 2026." What is Irritable Bowel Syndrome (IBS) Diagnostics? How big is the Irritable Bowel Syndrome (IBS) Diagnostics Market? Market Overview & Coverage: Irritable bowel syndrome is a medical condition that pertains to irregular bowel movement and is accompanied by extreme pain in the stomach followed by diarrhoea, cramping, and constipation among others.

The controversial Johnson & Johnson (NYSE: JNJ ) bankruptcy strategy will face a fresh trial to urge a judge to allow it to use the bankruptcy process to resolve claims that its talc-based products caused cancer . More than 38,000 plaintiffs have alleged the Company''s talc products caused ovarian cancer and mesothelioma, deadly cancer linked to asbestos exposure. J&J maintains that its consumer talc products are safe Full story available on Benzinga.com

Stock futures slide as U.S. Warns of Russian attack on Ukraine; Week Ahead: retail sales, Walmart earnings in focus; oil prices top $95 a barrel on Russia tensions, supply slump; Johnson & Johnson set to defend ''Texas Two Step'' on cancer liabilities and Coinbase QR code ad leads to web traffic "throttle".

Those who have received two doses of the Moderna or Pfizer-BioNTech COVID-19 vaccine or a single dose of the Johnson & Johnson vaccine no

The controversial Johnson & Johnson bankruptcy strategy thats drawn ire from Congress faces a fresh trial this week, with the consumer products giant set to argue that settling billions of dollars of talc liabilities in a single case is better for cancer victims than fighting thousands of individual claims.

Benzinga has examined the prospects for many investor favorite stocks over the past week. Last week''s bullish calls included an at-home digital exercise company and a social media giant. A leading streaming service company along with one of the largest healthcare companies in the world were among the bearish calls seen. It was a turbulent week for the markets as investors took cover as tensions continue to grow between Russia and Ukraine and new data showed U.S. inflation hit 7.5% in January. The latest number makes it more likely that the Federal Reserve will tighten monetary policy more aggressively than originally thought. All three major indexes experienced losses for the week. The S&P 500 and Nasdaq Composite were down 1.8% and 2.2%, respectively, while the Dow ended the week with a 1% loss. Benzinga continues to examine the prospects for many of the stocks most popular with investors. Here are a few of this past week''s most bullish and bearish posts that are worth another look. The Bulls " Peloton

Legend Biotech (LEGN) announced the achievement of two milestones under its collaboration with Janssen Biotech of Johnson & Johnson (JNJ) for cilta-cel.Also called…

Scientists have revealed data from their final analysis of Johnson & Johnson''s (NYSE: JNJ ) COVID-19 Phase 3 study, showing the vaccine may be even less effective in the longer term. The scientists tracked about 39,000 participants for a median of four months (8,940 of whom had at least six months of follow-up), researchers concluded in a paper published in the New England Journal of Medicine. Data showed that a single dose of Ad26.COV2.S Full story available on Benzinga.com

Johnson & Johnson''s single-shot COVID-19 vaccine was found to provide just 52.9% protection against moderate-to-severe disease at least 28 days after administration.

NEW YORK and MEMPHIS, Tenn. , Feb. 10, 2022 /PRNewswire/ -- HealthpointCapital Management LLC ("HealthpointCapital") is pleased to announce it has completed the sale of CrossRoads Extremity Systems ("CrossRoads, or the "Company") to DePuy Synthes, The Orthopaedics Company of Johnson & Johnson. The transaction marks the first exit for HealthpointCapital''s Musculoskeletal Fund. HealthpointCapital acquired a majority stake in CrossRoads in May 2019 and proceeded to further the Company''s position as the innovation leader in its segment. CrossRoads, founded in 2014 and headquartered in Memphis, TN , is a pure-play, innovative designer and manufacturer of procedure-specific, sterile-packed implants and instruments for elective foot and ankle surgery. Under HealthpointCapital''s ownership, CrossRoads also successfully broadened the Company''s product portfolio with the asset acquisitions of First Ray LLC, Kator LLC Full story available on Benzinga.com

A member of the Philadelphia Fire Department prepares a dose of the Johnson & Johnson COVID-19 vaccine at a vaccination site in Philadelphia on March 26, 2021. Johnson & Johnson has reportedly stopped the production of its single-dose COVID-19 vaccine. | Matt Rourke, Associated Press Can you still get the Johnson & Johnson COVID-19 vaccine? Johnson & Johnson has reportedly stopped the production of its single-dose COVID-19 vaccine, signaling that the company may cut back on its overall production of the vaccine. The news: The New York Times reports that Johnson & Johnson quietly shut down production at a plant in the Netherlands, which was the only location that was creating usable doses of the J&J COVID-19 vaccine. Yes, but: The facility, in the Dutch city of Leiden, has instead been making an experimental but potentially more profitable vaccine to protect against an unrelated virus, per The New York Times The halt in production will last temporarily, per The New York Times . Its unclear if the shutdown will impact overall J&J vaccine supplies because there are stockpiles of the vaccine available.